<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2018.81001</article-id><article-id pub-id-type="publisher-id">WJCR-22959</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20180100000_70718493.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  尼洛替尼联合三氧化二砷对K562细胞增殖及凋亡的影响
  The Effects of Nilotinib and Arsenic Trioxide on the Proliferation and Apoptosis of K562 Cells
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>高</surname><given-names>晓晗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>杰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>洁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>瑞仓</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>素云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>洪岭</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>河北省人民医院血液科，河北 石家庄</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>h0707@163.com(郝洪)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2017</year></pub-date><volume>08</volume><issue>01</issue><fpage>1</fpage><lpage>5</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探讨尼洛替尼(AMN107)与三氧化二砷(ATO)是否具有协同作用，为寻找慢性髓细胞白血病治疗新方法提供理论基础。方法：体外培养K562细胞，分别加入AMN107、ATO及两者联合干预细胞生长；MTT法检测药物对K562细胞增殖的影响；流式细胞仪检测药物对K562细胞凋亡的影响；流式细胞仪检测药物对K562细胞的细胞周期的影响；RT-PCR检测各组K562细胞BCR-ABL融合基因表达水平的变化。结果：MTT结果示AMN107、ATO均能够抑制K562细胞的生长，但两者联合较单药效果更佳，差异有统计学意义(P &lt; 0.05)。流式细胞仪检测细胞凋亡率(%)，AMN107 (10 umol/L)凋亡率为74.86 &#177; 1.86，ATO (5 umol/L)凋亡率为24.12 &#177; 2.03，两者联合可达到84.60 &#177; 1.80。RT-PCR检测显示ATO联合AMN107作用于K562细胞24 h、48 h、72 h后BCR/ABL融合基因的RQ比值分别为：0.51 &#177; 0.00、0.46 &#177; 0.00、0.37 &#177; 0.02。比两者单用BCR/ABL的比值更低。差异有统计学意义(P &lt; 0.05)。 Objective: To explore whether Nilotinib (AMN107) and arsenic trioxide (ATO) had synergistic effect, to provide theoretical basis for the new treatment of chronic myelocytic leukemia. Methods: K562 cells were cultivated in vitro, treated with AMN107, ATO or both; Cell proliferation of K562 cells were evaluated by using a MTT assay. Cell apoptosis of K562 cells were examined by using Flow cytometry. Cell cycle of K562 cells were anlysised by using Flow cytometry. The expression levels of BCR-ABL fusion genes of K562 cells were analyzed by using PT-PCR. Results: MTT shows that both of the AMN107 and ATO can inhibit the growth of the cells of K562, the combination of the two drugs was better than single one. Flow cytometry detected the cell apoptosis (%), AMN107 (10 umol/L) was 74.86 &#177; 1.86, ATO (5 umol/L) was 24.12 &#177; 2.03, the combination were 84.60 &#177; 1.80. RT-PCR shows that the combination group treated with the K562 cells after 24 h, 48 h, 72 h, the RQ of BCR/ABL were: 0.51 &#177; 0.00, 0.46 &#177; 0.00, 0.37 &#177; 0.02. The results were better than single one (P &lt; 0.05).
    
  
 
</p></abstract><kwd-group><kwd>尼洛替尼，三氧化二砷，K562细胞，凋亡, Nilotinib</kwd><kwd> Arsenic Trioxide</kwd><kwd> K562</kwd><kwd> Apoptosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>尼洛替尼联合三氧化二砷对K562细胞增殖及凋亡的影响<sup> </sup></title><p>高晓晗，李杰，杨洁，袁军，王瑞仓，李燕，王素云，郝洪岭<sup>*</sup></p><p>河北省人民医院血液科，河北 石家庄</p><disp-formula id="hanspub.22959-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2150120x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年11月16日；录用日期：2017年11月30日；发布日期：2017年12月8日</p><disp-formula id="hanspub.22959-formula4"><graphic xlink:href="//html.hanspub.org/file/1-2150120x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨尼洛替尼(AMN107)与三氧化二砷(ATO)是否具有协同作用，为寻找慢性髓细胞白血病治疗新方法提供理论基础。方法：体外培养K562细胞，分别加入AMN107、ATO及两者联合干预细胞生长；MTT法检测药物对K562细胞增殖的影响；流式细胞仪检测药物对K562细胞凋亡的影响；流式细胞仪检测药物对K562细胞的细胞周期的影响；RT-PCR检测各组K562细胞BCR-ABL融合基因表达水平的变化。结果：MTT结果示AMN107、ATO均能够抑制K562细胞的生长，但两者联合较单药效果更佳，差异有统计学意义(P &lt; 0.05)。流式细胞仪检测细胞凋亡率(%)，AMN107 (10 umol/L)凋亡率为74.86 &#177; 1.86，ATO (5 umol/L)凋亡率为24.12 &#177; 2.03，两者联合可达到84.60 &#177; 1.80。RT-PCR检测显示ATO联合AMN107作用于K562细胞24 h、48 h、72 h后BCR/ABL融合基因的RQ比值分别为：0.51 &#177; 0.00、0.46 &#177; 0.00、0.37 &#177; 0.02。比两者单用BCR/ABL的比值更低。差异有统计学意义(P &lt; 0.05)。</p><p>关键词 :尼洛替尼，三氧化二砷，K562细胞，凋亡</p><disp-formula id="hanspub.22959-formula5"><graphic xlink:href="//html.hanspub.org/file/1-2150120x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2150120x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2150120x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>慢性髓细胞白血病(chronic myelocytic leukemia, CML)是一种发生在多能造血干细胞上的恶性骨髓增殖性肿瘤，其特异性表达BCR/ABL融合基因，编码P210蛋白，具有酪氨酸激酶活性，从而导致CML的发生。分子靶向药物——酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)的问世，为CML的治疗带来了革命性的进展。然而TKIs治疗过程中出现的耐药或不耐受的情况使得疾病治疗中断，甚至部分CML患者出现疾病复发等问题迫使人们进一步探索新的治疗策略。本研究通过体外培养慢性髓细胞白血病细胞株K562细胞，经尼洛替尼(AMN107)、三氧化二砷(ATO)或两者联合干预，观察K562细胞的增殖及凋亡的情况，比较药物干预前后BCR-ABL基因表达水平的变化，探讨两药是否具有协同作用，现报道如下。</p></sec><sec id="s4"><title>2. 材料与方法</title><p>1) 主要材料：K562细胞由河北医科大学第二医院赠送；ATO购自美国sigma公司；AMN107为诺华公司赠送。</p><p>2) 细胞培养：体外培养K562细胞。分为空白对照组与实验组。空白对照组只加培养基和细胞；实验组分为AMN107组、ATO组和AMN107 + ATO组，共3组，培养3天。</p><p>3) MTT法检测细胞增殖：取各组K562细胞，调节细胞浓度为1 &#215; 106/ml，接种于96孔板中，每组设6个平行孔，培养终止前4 h每孔加入MTT (5 mg/ml) 20 μl，继续培养4 h，每孔加入三联液100 μl，震荡30 min，放入培养箱中过夜。置酶标仪读取吸光度A值。根据如下公式计算细胞生长抑制率：细胞生长抑制率 = [对照组A值 − 实验组A值]/对照组A值 &#215; 100%。</p><p>4) 流式细胞仪检测细胞周期：收集各组K562细胞，PBS洗2次，70%乙醇固定。固定好的细胞1500 r/min，5 min，离心去上清，用1 ml PBS重悬，400目筛网过滤1次。取200 μl细胞悬液加800 μl碘化丙啶(PI)染液，混匀，避光染色30 min。用流式细胞仪检测，ModFit LT软件进行细胞周期分析。</p><p>5) Annexin V-FITC/PI染色法流式细胞仪检测细胞凋亡：取各组K562细胞，接种于12孔板中，培养48 h，将培养板中的细胞转移到流式管中，1200 rpm，10 min，弃上清，调节细胞数为1 &#215; 10<sup>5</sup>~1 &#215; 10<sup>6</sup>个，将细胞重悬于200 μl Buffer中，加入10 μl Annexin V-FITC和5 μl PI，震荡1 min，加入10 μl Annexin V-FITC和5 μl PI，震荡1 min，上流式细胞仪检测。</p><p>6) RT-PCR检测BCR/ABL融合基因的表达：取各组K562细胞，提取总RNA，逆转录为cDNA后进行基因扩增。BCR引物序列：上游：5'-GAGAGAAGAGGGCGAACAA-3'，下游：5'-GACATAAGCAGCAG CAGTGAC-3'。ABL引物序列：上游：5'-ACATCACGCCAGTCAACAG-3'，下游：5'-GCAGATACTCAGCGG CATT-3'。反应体系20 ul：样品8 ul，Mix酶10 ul，Primer 1 ul + 1 ul。反应条件：96℃ 4 min，94℃ 30 s，58℃ 30 s，72℃ 30 s，循环40次。结果检测：扩增完毕后，进入结果分析界面，以GAPDH为内参照基因，与对照组相比(对照组RQ值为1.0)，得到目的基因表达的相对定量值(RQ值)，将RQ值用于统计分析。</p><p>7) 应用spss13.0进行统计学分析。</p></sec><sec id="s5"><title>3. 结果</title><p>1) AMN107与ATO对K562细胞增殖的影响：MTT结果示：AMN107或ATO对K562细胞增殖均有抑制作用且呈剂量和时间依赖性。AMN107联合ATO组较两药单独应用细胞生长抑制率更高，见表1。</p><p>2) AMN107与ATO对K562细胞增殖的影响：AMN107或ATO均可引起K562细胞的凋亡，且两者联合较单药对引起K562细胞的凋亡率更高，见表2。</p><p>3) ATO对K562细胞周期分布的影响：5 umol/L ATO处理K562细胞后，G0/G1期细胞的比例(%)较对照组明显增加(38.57 &#177; 0.39 vs 18.65 &#177; 0.33，P &lt; 0.05)。</p><p>4) AMN107联合ATO较AMN107或ATO单药作用使得K562细胞表达BCR-ABL基因表达水平更低，详细结果见表3。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Growth inhibitory rate treated with different drugs (%, x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Concentration (uM)</th><th align="center" valign="middle" >Time (24 h)</th><th align="center" valign="middle" >Time (48 h)</th><th align="center" valign="middle" >Time (72 h)</th></tr></thead><tr><td align="center" valign="middle" >ATO AMN107</td><td align="center" valign="middle" >1 2.5 5 2.5 5 10</td><td align="center" valign="middle" >10.25 &#177; 1.38 20.38 &#177; 1.27 25.58 &#177; 1.69 30.27 &#177; 1.58 51.55 &#177; 2.72 62.74 &#177; 1.77</td><td align="center" valign="middle" >15.88 &#177; 1.11 24.75 &#177; 1.45 34.06 &#177; 1.20 35.34 &#177; 1.00 58.64 &#177; 1.45 67.05 &#177; 1.63</td><td align="center" valign="middle" >20.07 &#177; 1.46 30.59 &#177; 1.72 48.30 &#177; 2.26 45.65 &#177; 1.84 63.44 &#177; 1.70 72.07 &#177; 1.74</td></tr><tr><td align="center" valign="middle"  colspan="2"  >AMN107 (10) + ATO (5)</td><td align="center" valign="middle" >72.06 &#177; 2.19</td><td align="center" valign="middle" >81.36 &#177; 1.24</td><td align="center" valign="middle" >85.24 &#177; 1.36</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 不同药物对生长抑制率的影响</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Apoptosis rate treated with ATO, AMN107, ATO + AMN107 (%, x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Concentration</th><th align="center" valign="middle" >Control group</th><th align="center" valign="middle"  colspan="3"  >ATO</th><th align="center" valign="middle"  colspan="3"  >AMN107</th><th align="center" valign="middle" >Combined group</th></tr></thead><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.5</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >10 + 5</td></tr><tr><td align="center" valign="middle" >Rate</td><td align="center" valign="middle" >2.26 &#177; 0.63</td><td align="center" valign="middle" >4.21 &#177; 0.62</td><td align="center" valign="middle" >4.21 &#177; 0.62</td><td align="center" valign="middle" >24.12 &#177; 2.03</td><td align="center" valign="middle" >30.00 &#177; 1.48</td><td align="center" valign="middle" >63.78 &#177; 1.91</td><td align="center" valign="middle" >74.86 &#177; 1.86</td><td align="center" valign="middle" >84.60 &#177; 1.80</td></tr></tbody></table></table-wrap><p>表2. 三氧化二砷、尼洛替尼以及两者联合对细胞凋亡的影响</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Expression levels of BCR-ABL after treatment of AMN107, ATO, ATO + AMN107 ( x &#175; &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Concentration (uM)</th><th align="center" valign="middle" >Time (24 h)</th><th align="center" valign="middle" >Time (48 h)</th><th align="center" valign="middle" >Time (72 h)</th></tr></thead><tr><td align="center" valign="middle" >Control group ATO AMN107</td><td align="center" valign="middle" >0 1 2.5 5 2.5 5 10</td><td align="center" valign="middle" >1.39 &#177; 0.07 1.12 &#177; 0.02 1.01 &#177; 0.01 0.89 &#177; 0.00 0.84 &#177; 0.02 0.78 &#177; 0.02 0.66 &#177; 0.03</td><td align="center" valign="middle" >1.22 &#177; 0.03 1.06 &#177; 0.01 0.94 &#177; 0.01 0.85 &#177; 0.01 0.79 &#177; 0.02 0.72 &#177; 0.02 0.59 &#177; 0.01</td><td align="center" valign="middle" >1.18 &#177; 0.02 1.02 &#177; 0.01 0.91 &#177; 0.01 0.79 &#177; 0.00 0.71 &#177; 0.02 0.63 &#177; 0.01 0.51 &#177; 0.01</td></tr><tr><td align="center" valign="middle"  colspan="2"  >AMN107 (10) + ATO (5)</td><td align="center" valign="middle" >0.51 &#177; 0.00</td><td align="center" valign="middle" >0.46 &#177; 0.00</td><td align="center" valign="middle" >0.37 &#177; 0.02</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 不同药物对BCR-ABL基因表达水平的影响</p></sec><sec id="s6"><title>4. 讨论</title><p>在CML中，BCR-ABL融合基因转录为8.5 kb的mRNA，并翻译产生分子量为210 KD的BCR-ABL融合蛋白P210BCR-ABL，该蛋白编码的产物具有酪氨酸激酶活性 [<xref ref-type="bibr" rid="hanspub.22959-ref1">1</xref>] ，能磷酸化多种蛋白质底物上的酪氨酸残基，作用于BCR-ABL下游的一系列信号转导通路，导致CML的发生。TKIs的问世为CML的治疗带来了革命性的进展，它能特异性阻断ATP在abl激酶上的结合位置，使酪氨酸残基不能磷酸化，从而抑制BCR-ABL阳性细胞增殖。本研究以不同浓度AMN107作用于K562细胞3天后发现BCR-ABL融合基因的表达水平明显下降，细胞生长抑制率及细胞凋亡率明显增加。KJ、Landry [<xref ref-type="bibr" rid="hanspub.22959-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.22959-ref3">3</xref>] 等的研究也证实了这一结论。</p><p>然而TKIs对CML的起始干细胞(Lekumia intial cells, LICs)无作用，导致部分患者出现耐药或停药后复发，或由于点突变、基因扩增等产生TKIs耐药或不耐受等问题，因此寻找新的治疗靶点是我们目前迫切需要的 [<xref ref-type="bibr" rid="hanspub.22959-ref4">4</xref>] 。目前研究热点为利用不同化疗药物的作用靶点及机制的不同增加各个化疗药物对肿瘤细胞的杀伤力，或联合用药以减少单药高剂量带来的毒副作用及耐药。</p><p>我国学者自19世纪70年代开始应用砷制剂治疗白血病，目前ATO在治疗急性早幼粒细胞白血病(APL)方面已取得巨大进展，最近发现ATO在CML治疗中也有一定的价值，Dennis J及Luo报道ATO作用于K562细胞能通过诱导细胞自噬等途径下调BCR-ABL基因的表达 [<xref ref-type="bibr" rid="hanspub.22959-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.22959-ref6">6</xref>] 。Dennis同时报道ATO可以通过自噬性溶酶体和蛋白酶介导的降解组织蛋白酶B上的P62/SQSTM1而靶向作用于BCR-ABL融合基因，使其表达水平下调。Luo等发现ATO能够通过抑制VEGF的表达，继而阻断其下游一系列信号途径包括PI3K/PIP3/Akt/PKB、MAPKAPK2/HSP27和Ras/MEK/ERK，下调BCR-ABL融合基因水平，阻断CML的发生。ATO还能阻断细胞周期进程，使之不能进入S期完成有丝分裂，从而抑制细胞增殖 [<xref ref-type="bibr" rid="hanspub.22959-ref7">7</xref>] 。本研究应用流式细胞仪检测经ATO干预后的K562细胞的细胞周期的变化，结果显示，ATO作用于K562细胞后使停滞在G0/G1期的K562细胞比例增加，S期、G2M期细胞比例减少。应用RT-PCR比较ATO干预K562细胞前后BCR-ABL基因表达的变化发现ATO能降低BCR-ABL基因的表达水平。</p><p>本研究结果显示AMN107与ATO均能够诱导细胞凋亡，AMN107诱导K562细胞凋亡的能力是ATO的2~3倍，然而黄先豹报道AMN107 (5 umol/L)与ATO (5 umol/L)干预K562细胞后细胞凋亡率分别为60.98 &#177; 2.46 vs 60.98 &#177; 2.28，两者效果相等，与本研究结果存在一定的差异，考虑可能与细胞株来源不同、作用时间不同等有关。Xia Y [<xref ref-type="bibr" rid="hanspub.22959-ref8">8</xref>] 等研报道AMN107与ATO在诱导K562细胞凋亡方面存在协同作用。本研究也证实AMN107与ATO两者联合作用于K562细胞，细胞生长抑制率和凋亡率均较两者应用效果更佳，BCR-ABL基因表达水平较两者单独作用表达更低，因此推测ATO与AMN107能够通过不同的作用途径协同抑制BCR-ABL基因的表达。然而两者具体是作用于哪些信号分子而协同发挥效应的，是我们今后进一步研究的方向。</p></sec><sec id="s7"><title>文章引用</title><p>高晓晗,李 杰,杨 洁,袁 军,王瑞仓,李 燕,王素云,郝洪岭. 尼洛替尼联合三氧化二砷对K562细胞增殖及凋亡的影响The Effects of Nilotinib and Arsenic Trioxide on the Proliferation and Apoptosis of K562 Cells[J]. 世界肿瘤研究, 2018, 08(01): 1-5. http://dx.doi.org/10.12677/WJCR.2018.81001</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.22959-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Simonsson, B., Hjorth-Hansen, H., Bjerrum, O.W., et al. (20l1) Inteiteron Alpha for Treatment of Chronic Myeloid Leukemia. Current Drug Targets, 12, 420-428.</mixed-citation></ref><ref id="hanspub.22959-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Aichberger, K.J., Mayerhofer, M., Krauth, M.T., et al. (2005) Low-Level Expression of Proapoptotic Bcl-2-Interacting Mediator in Leukemic Cells in Patients with Chronic Myeloid Leukemia: Role of BCR/ABL, Characterization of Un-derlying Signaling Pathways, and Reexpression by Novel Pharmacologic Compounds. Cancer Research, 65, 9436-9444. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-05-0972</mixed-citation></ref><ref id="hanspub.22959-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Landry, W.D., Woolley, J.F., Cotter, T.G., et al. (2013) Imatinib and Nilotinib Inhibit BCR-ABL-Induced ROS through Targeted Degradation of the NADPH Oxidase Subunit p22phox. Leukemia Re-search, 37, 183-189.  
&lt;br&gt;https://doi.org/10.1016/j.leukres.2012.11.003</mixed-citation></ref><ref id="hanspub.22959-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Lv, F.F., Du, Y., Chen, L., et al. (2015) The Effect of Nilotinib Plus Arsenic Trioxide on Theproliferation and Differentiation of Primary Leukemic Cells from Patients with Chronic Myoloid Leu-kemia in Blast Crisis. Cancer Cell International, 15, 10.</mixed-citation></ref><ref id="hanspub.22959-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Luo, X.C., Feng, M.X., Zhu, X.J., et al. (2013) VEGF Depletion En-hances BCR-ABL-Specific Sensitivity of Arsenic Trioxide in Chronic Myelogenous Leukemia. Hematology, 18, 334-340.  
&lt;br&gt;https://doi.org/10.1179/1607845413Y.0000000083</mixed-citation></ref><ref id="hanspub.22959-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dennis, J.G., Elias, G., Edward, J., et al. (2012) Autophagic Degrada-tion of the BCR-ABL Oncoprotein and Generation of Antileukemic Responses by Arsenic Trioxide. Blood, 120, 3555-3562.  
&lt;br&gt;https://doi.org/10.1182/blood-2012-01-402578</mixed-citation></ref><ref id="hanspub.22959-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jing, Y., Wang, L., Xia, L., et al. (2001) Combined Effect of All-Trans Retinoic Acid and Arsenic Trioxide in Acute Promyeloeytie Leukemia Cells In Vitro and In Vivo. Blood, 97, 264-269. &lt;br&gt;https://doi.org/10.1182/blood.V97.1.264</mixed-citation></ref><ref id="hanspub.22959-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Xia, Y., Fang, H., Zhang, J., et al. (2013) Endoplasmic Reticulum Stress-Mediated Apoptosis in Imatinib-Resistant Leukemic K562-r Cells Triggered by AMN107 Combined with Arsenic Trioxide. Experimental Biology and Medicine (Maywood), 238, 932-942. &lt;br&gt;https://doi.org/10.1177/1535370213492689</mixed-citation></ref></ref-list></back></article>